Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MRVI
SellHot AirMaravai LifeSciences Holdings, Inc. · Healthcare · United States · $2.8B · Avg Vol: $26M/d
COMPANY DESCRIPTION
Maravai LifeSciences Holdings, Inc. is a leading provider of critical nucleic acid synthesis products and biologics safety testing services essential for the development of vaccines, novel therapies, and diagnostics. The company maintains a strong competitive moat through its highly specialized expertise, proprietary technologies, and stringent quality control, serving top biopharmaceutical and academic clients. Maravai is a key enabler in the rapidly expanding fields of mRNA therapeutics, gene editing, and cell therapies, benefiting from high regulatory barriers and deep customer integration.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 883.0M | 288.9M | 259.2M | 185.7M | -40.5% | 208.8M | 211.6M | 225.7M | 10.2% |
| EPS | 1.59 | 1.67 | -0.90 | -1.05 | -0.90 | 5.0% | -0.53 | — | — | — |
| Shares | — | 131.7M | 132.2M | 142.0M | 145.3M | +10.4% | 149.0M | — | — | — |
| Debt | — | 585.3M | 611.0M | 376.7M | 364.7M | -14.6% | 218.1M | — | — | — |
| Equity | — | 545.2M | 416.8M | 325.3M | 212.4M | -27.0% | — | — | — | — |
| Op CF | — | 536.0M | 126.2M | 7.5M | -57.6M | -88.2% | -25.3M | — | — | — |
| Inv CF | — | -267.6M | -122.3M | -24.3M | -31.4M | — | — | — | — | — |
| Fin CF | — | -187.5M | -61.1M | -235.7M | -16.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MRVI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MRVI | Maravai LifeSciences Holdings, Inc.(you) | $2.8B | 24 | Sell |
| ATAI | AtaiBeckley Inc. | $2.7B | 23 | Sell |
| CLDX | Celldex Therapeutics, Inc. | $3.1B | 25 | Sell |
| IRON | Disc Medicine, Inc. | $3.1B | 22 | Sell |
| NKTR | Nektar Therapeutics | $2.5B | 23 | Sell |
| MBX | MBX Biosciences, Inc. | $3.0B | 28 | Sell |
| NRIX | Nurix Therapeutics, Inc. | $2.7B | 28 | Sell |
| IMNM | Immunome, Inc. | $3.1B | 20 | Strong Sell |
| PGEN | Precigen, Inc. | $2.5B | 28 | Sell |
| TRVI | Trevi Therapeutics, Inc. | $2.4B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%